Q1 FY27 results analysis · July 31, 2026

Narayana Hrudayalaya Q1 FY27 Results Analysis: PAT Jumps 58%, EBITDA Margin Compresses 511bps (NH)

+5.7%PAT year on year, Rs. 207.27 Cr
Cofacto ResearchPublished July 31, 20262 min readNeutral read
Quick summary

Narayana Hrudayalaya Ltd's Q1 FY27 numbers came in mixed, with revenue of Rs. 2,683.63 Cr (+78.05% YoY) and PAT growth of +5.72% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quick Details
Results dateJuly 31, 2026
QuarterQ1 FY 2026-2027
Revenue (Q1)Rs. 2,683.63 Cr (+78.05% YoY)
PAT (Q1)Rs. 207.27 Cr (+5.72% YoY)
EBITDA margin18.82% (-511 bps YoY)
EPS (Q1)Rs. 10.20 (+5.70% YoY)
Market capRs. 41,487.84 Cr
CMPRs. 2,029.20

Quarter Snapshot

Standalone India business delivered strong 16.3% revenue growth and 57.8% PAT growth with expanding margins, indicating healthy core operations. However, consolidated results are weighed down by UK acquisition margin dilution (EBITDA margin compressed 511bps YoY) and a widening insurance loss (Rs.62.5 Cr per quarter). The UK integration trajectory and insurance turnaround are critical for future performance.

Key Investment Insights

Key Positives

  • Standalone revenue grew 16.3% YoY to Rs.1,097 Cr
  • Standalone PAT grew 57.8% YoY to Rs.137.85 Cr
  • Standalone EBITDA margin expanded 385 bps YoY to 24.57%
  • Consolidated revenue grew 78% YoY to Rs.2,683.6 Cr, driven by full quarter of UK acquisition
  • Debt/equity improved sequentially from 1.29x to 1.24x
  • No exceptional items in Q1 FY27; auditor's report clean
  • Medical supplies cost improved to 19.16% of revenue from 20.29% YoY

Risk Factors

  • Consolidated EBITDA margin compressed 511 bps YoY and 197 bps QoQ to 18.82%
  • PAT-to-owners grew only 5.35% despite 78% revenue growth
  • Insurance segment loss widened to Rs.62.5 Cr from Rs.24 Cr YoY, annualising ~Rs.250 Cr drag
  • Medical segment margin compressed sequentially to 14.73% from 16.66%
  • Finance costs rose 92% YoY to Rs.86.8 Cr due to UK acquisition debt

Ask about this

Ask Cofacto a question about this result. Answers cite filings and company data.

Companies on this page

Related

Share on X · LinkedIn · WhatsApp

Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.